XL147 (SAR245408)

DRUG6 trials

Sponsors

Sanofi

Conditions

Astrocytoma, Grade IVBreast CancerBreast NeoplasmsCancerEndometrial CancerEndometrial NeoplasmsGlioblastomaLymphoma

Phase 1

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

CompletedNCT00486135

SanofiCancer, Lymphoma

Start: 2007-06-30End: 2012-10-31Updated: 2013-02-01

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

CompletedNCT00692640

SanofiCancer, Non-small Cell Lung Cancer

Start: 2008-05-31End: 2011-11-30Updated: 2012-03-23

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

CompletedNCT01042925

SanofiBreast Cancer, Breast Neoplasms

Start: 2010-02-28End: 2012-12-31Updated: 2016-06-03

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

CompletedNCT01082068

SanofiBreast Cancer

Start: 2010-06-30End: 2013-04-30Updated: 2016-06-03

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

CompletedNCT01240460

SanofiAstrocytoma, Grade IV, Glioblastoma

Start: 2011-01-31End: 2012-06-30Updated: 2012-07-27

Phase 2

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

CompletedNCT01013324

SanofiEndometrial Cancer, Endometrial Neoplasms

Start: 2010-01-31End: 2013-03-31Updated: 2016-06-03

Related Papers

Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients

Blood2013-11-1510 citations